RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents
RegeneRx Biopharmaceuticals, Inc. announced today that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
Read more on News-Medical-Net
Orignal From: RegeneRx receives patent for Tβ4 to prevent immunological responses from toxic agents
Post a Comment